MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--VIVUS, Inc (NASDAQ: VVUS) a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that the results from OB-202, a 28-week, placebo controlled, safety and efficacy phase 2 study to determine glycemic control in type 2 diabetics treated with Qnexa, will be delivered as a podium presentation during the American Diabetes Association (ADA) meeting in San Francisco, California, by Dr. Timothy Garvey, at 7:30 am PT Tuesday June 10, 2008.
